Development Partners International, a private equity firm, and Amethis, an investment fund, completed the investment in Marcyrl, an Egyptian pharmaceuticals manufacturer focused on specialty generics. Financial terms were not disclosed. “At Marcyrl, we are working to transform the way specialty treatments are made accessible across Egypt and the entire African continent, ensuring that specialty care treatments are available to those that need them the most. Building on our 22 years of success, we will continue to innovate across our products, particularly in high-growth areas of specialty generics, developing much needed treatments to customers across the continent. We are pleased to welcome DPI and Amethis as new global investors and look forward to working with them to accelerate our growth and explore new opportunities to deliver cost-effective, critical solutions to healthcare practitioners and their patients across Egypt and Sub-Saharan Africa,” Farid Habib Salib, Marcyrl Pharmaceutical Industries Chairman.